BOZEMAN, MT, August 18, 2010
/24-7PressRelease/ -- BioScience Laboratories has obtained seven clinical isolates of Carbapenem-Resistant (CR) Klebsiella pneumoniae and Escherichia coli.
These organisms provide a strong model for predicting a product's efficacy against "Super-Bugs," such as the New Delhi metallo-a-lactamase 1 (NDM-1) strain that has aroused recent worldwide concern. Carbapenems are historically used as a last resort for fighting bacterial infections, particularly versus multidrug-resistant Gram-negative species.
The five isolates of CR-Klebsiella pneumoniae and two isolates of CR-Escherichia coli are being used by BioScience Laboratories microbiologists to test products for their in-vitro efficacy as topical antimicrobials or hard-surface disinfectants to provide data predictive of a product's efficacy versus the New Delhi metallo-a-lactamase 1 (NDM-1) strain.
BioScience Laboratories, Inc. was founded in 1991 in Bozeman, MT, to provide antimicrobial product testing and result interpretation grounded in science. Bioscience Laboratories Inc. strives to assist its clients in strengthening their current market positions through product testing and aid in the development of new products and new markets. Today, BioScience Laboratories offers a variety of state-of-the-art laboratory services and guidance regarding federal regulatory agency requirements for the healthcare, pharmaceutical, personal care and consumer products markets.
Website:
http://www.biosciencelabs.com---
Press release service and press release distribution provided by http://www.24-7pressrelease.com# # #
Press Release Keywords:- bioscience laboratories, carbapenem-resistant (cr) klebsiella pneumoniae, escherichia coli, product efficacy, super-bugs, new delhi metallo-â-lactamase 1, ndm-1, carbapenems, bacterial infections, multidrug-resistant, in-vitro efficacy, topical antimicrobials, hard-surface disinfectants
Read more Press Releases from John Dyba:
